| Revenue growth | FY26 standalone revenue declined 12% YoY. |
|---|---|
| Margins | Q4FY26 EBITDA margin improved to 17% from 16% YoY. |
| Demand visibility | Targeting 15-20% API and 80% FDF in $15Bn cephalosporin market. |
| Management confidence | High; stating turnaround is complete and platform creation is beginning. |
Growth
FY26 Revenue down 12% YoY (₹811 Cr vs ₹922 Cr); Q4FY26 PAT up 7% YoY to ₹30 Cr.
Outlook
₹750 Cr capex for 7ACA project (FY27 commissioning); plans for 5-6 sterile US launches by 2030.
Risks
Heavy dependence on cephalosporin segment (90%); ongoing execution risks for large-scale capex projects in Jammu.
Earnings Call filed with NSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹1,064.90
- Market cap
- ₹6,377 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 735.8×Sector 50.4×
- Promoter holding
- 69.84%+0.00% QoQ
- FII holding
- 0.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Capital Structure Change
Orchid Pharma Limited received trading approval for 4,45,86,052 equity shares issued under its NCLT-sanctioned scheme of amalgamation, effective September 23, 2026.
Orchid Pharma Acquisition
Orchid Pharma purchased land in Patibulum Village, Kancheepuram District. This transaction concludes the previous lease arrangement with DBS Bank regarding the property.
Orchid Pharma Annual Report
Orchid Pharma has filed its Annual Report for the financial year 2025-26, which includes the notice for the company's 33rd Annual General Meeting.
Orchid Pharma Annual General Meeting
Orchid Pharma Limited has issued the notice for its 33rd Annual General Meeting scheduled for September 29, 2026, to conduct ordinary and special business.
Orchid Pharma Management Change
Orchid Pharma Limited announced the redesignation of Mr. Arjun Dhanuka as Executive Director and the appointment of M/s. J Karthikeyan & Associates as Cost Auditors.
Orchid Pharma Board Meeting Outcome
Orchid Pharma appointed a cost auditor and designated Mr. Arjun Dhanuka as a Whole-Time Director. The board also set arrangements for the upcoming 33rd Annual General Meeting.